Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bevacizumab plus irinotecan in recurrent glioblastoma.

× No keyword cloud information.

19 in total

1. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.

Authors: Ufuk Abacioglu; Hale B Caglar; Perran F Yumuk; Zuleyha Akgun; Beste M Atasoy; Meric Sengoz
Journal: J Neurooncol Date: 2010-09-29 Impact factor: 4.130

2. Bevacizumab--news from the fast lane?

Authors: Michael Weller; W K Alfred Yung
Journal: Neuro Oncol Date: 2008-09-05 Impact factor: 12.300

3. Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Authors: Michael Back; Cecelia E Gzell; Marina Kastelan; Linxin Guo; Helen R Wheeler
Journal: Neurooncol Pract Date: 2014-12-15

Review 4. Anaplastic astrocytoma.

Authors: Sean A Grimm; Marc C Chamberlain
Journal: CNS Oncol Date: 2016-05-27

5. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model.

Authors: Véronique Mathieu; Nancy De Nève; Marie Le Mercier; Janique Dewelle; Jean-François Gaussin; Mischael Dehoux; Robert Kiss; Florence Lefranc
Journal: Neoplasia Date: 2008-12 Impact factor: 5.715

Review 6. Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.

Authors: Mohammad Tabrizi; Gadi Gazit Bornstein; Hamza Suria
Journal: AAPS J Date: 2009-11-19 Impact factor: 4.009

Review 7. Engineering lymphocyte subsets: tools, trials and tribulations.

Authors: Carl H June; Bruce R Blazar; James L Riley
Journal: Nat Rev Immunol Date: 2009-10 Impact factor: 53.106

8. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial.

Authors: Benjamin M Ellingson; Hyun J Kim; Davis C Woodworth; Whitney B Pope; Jonathan N Cloughesy; Robert J Harris; Albert Lai; Phioanh L Nghiemphu; Timothy F Cloughesy
Journal: Radiology Date: 2013-11-27 Impact factor: 11.105

9. Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients.

Authors: Myron Zhang; Bryanna Gulotta; Alissa Thomas; Thomas Kaley; Sasan Karimi; Igor Gavrilovic; Kaitlin M Woo; Zhigang Zhang; Julio Arevalo-Perez; Andrei I Holodny; Marc Rosenblum; Robert J Young
Journal: Neuro Oncol Date: 2015-11-03 Impact factor: 12.300

Review 10. GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity.

Authors: Alenoush Vartanian; Sanjay K Singh; Sameer Agnihotri; Shahrzad Jalali; Kelly Burrell; Kenneth D Aldape; Gelareh Zadeh
Journal: Neuro Oncol Date: 2014-03-18 Impact factor: 12.300